Raf Inhibitors Target Ras Spatiotemporal Dynamics

被引:49
|
作者
Cho, Kwang-jin [2 ]
Kasai, Rinshi S. [3 ]
Park, Jin-Hee [2 ]
Chigurupati, Sravanthi [2 ]
Heidorn, Sonja J. [1 ]
van der Hoeven, Dharini [2 ]
Plowman, Sarah J. [2 ]
Kusumi, Akihiro [3 ,4 ]
Marais, Richard [1 ]
Hancock, John F. [2 ]
机构
[1] Inst Canc Res, Sect Cell & Mol Biol, Signal Transduct Team, London SW3 6JB, England
[2] Univ Texas Med Sch Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA
[3] Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068507, Japan
[4] Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Kyoto 6068507, Japan
关键词
K-RAS; NANOCLUSTER FORMATION; TUMOR PROGRESSION; LIPID RAFTS; H-RAS; ACTIVATION; BRAF; ERK; DEPENDENCE; PROTEINS;
D O I
10.1016/j.cub.2012.03.067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The lateral segregation of Ras proteins into transient plasma membrane nanoclusters is essential for high-fidelity signal transmission by the Ras mitogen-activated protein kinase (MAPK) cascade. In this spatially constrained signaling system, the dynamics of Ras nanocluster assembly and disassembly control MAPK signal output. Results: We show here that BRaf inhibitors paradoxically activate CRaf and MAPK signaling in Ras transformed cells by profoundly dysregulating Ras nanocluster dynamics. Specifically, BRaf inhibitors selectively enhance the plasma membrane nanoclustering of oncogenic K-Ras and N-Ras but have no effect on H-Ras nanoclustering. Raf inhibitors are known to drive the formation of stable BRaf-CRaf and CRaf-CRaf dimers. Our results demonstrate that the presence of two Ras-binding domains in a single Raf dimer is sufficient and required to increase Ras nanoclustering, indicating that Raf dimers promote K- and N-Ras nanocluster formation by crosslinking constituent Ras proteins. Ras crosslinking increases the fraction cif K-Ras and N-Ras in their cognate nanoclusters, leading to an increase in MAPK output from the plasma membrane. Intriguingly, increased MAPK signaling in BRaf inhibited cells is accompanied by significantly decreased Akt activation. We show that this signal pathway crosstalk results from a novel mechanism of competition between stabilized Raf dinners and p110 alpha for recruitment to Ras nanoclusters. Conclusions: Our findings reveal that BRaf inhibitors disrupt Ras nanocluster dynamics with significant, yet divergent, consequences for MAPK and PI3K signaling.
引用
收藏
页码:945 / 955
页数:11
相关论文
共 50 条
  • [21] RAF, RAS and mismatch repair
    Weitzman J.B.
    Genome Biology, 3 (1)
  • [22] The Ras/Raf/MAPK pathway
    Molina, Julian R.
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (01) : 7 - 9
  • [23] Synergism between inhibitors of the EGFR-RAS-RAF-MEK pathway and the WNT pathway
    Cai, Jinjin
    Dorr, Andrew
    Rosenstein, Laurie
    Labdon, Jim
    Li, Xiaojuan
    Zhou, Hang
    Zhou, Yanyuan
    He, Wangjun
    He, Qiuping
    Huang, Xiaoyan
    Parikh, Aparna R.
    Giannakis, Marios
    An, Michael
    CANCER RESEARCH, 2023, 83 (08)
  • [24] Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
    Manousaridis, I.
    Mavridou, S.
    Goerdt, S.
    Leverkus, M.
    Utikal, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (01) : 11 - 18
  • [25] Raf promotes Ras dimerization
    Packer, Morgan
    Parker, Jillian
    Chung, Jean
    Li, Zhenlu
    Lee, Young
    Cookis, Trinity
    Guterres, Hugo
    Alvarez, Steven
    Hossain, M. D.
    Donnelly, Daniel
    Agar, Jeffrey
    Makowski, Lee
    Buck, Matthias
    Groves, Jay
    PROTEIN SCIENCE, 2021, 30 : 132 - 132
  • [26] RAF restrained and ready for RAS
    Eck, Michael
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2019, 75 : A220 - A220
  • [27] RAF Inhibitors
    Di Nicolantonio, F.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S68 - S68
  • [28] RAF inhibitors
    Utikal, Jochen
    Brummer, Tilman
    Zenz, Thorsten
    ONKOLOGE, 2017, 23 (08): : 639 - 644
  • [29] Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis
    Fritsche-Guenther, Raphaela
    Witzel, Franziska
    Kempa, Stefan
    Brummer, Tilman
    Sers, Christine
    Bluethgen, Nils
    ONCOTARGET, 2016, 7 (07) : 7960 - 7969
  • [30] Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors
    Gouda, Mohamed Alaa
    Lin, Heather Y.
    Kang, Lei
    Le, Hung
    Dumbrava, Ecaterina Elena
    Fu, Siqing
    Karp, Daniel D.
    Tsimberidou, Apostolia Maria
    Naing, Aung
    Piha-Paul, Sarina A.
    Pohlmann, Paula R.
    Ahnert, Jordi Rodon
    Yap, Timothy A.
    Meric-Bernstam, Funda
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)